SynthesisEuropean archives of psychiatry and clinical neuroscience2015
Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis.
Synthesis in European archives of psychiatry and clinical neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Pooled it
- Pharmacotherapy for smoking cessation in schizophrenia: a systematic review.Expert opinion on pharmacotherapy · 2020Pooled it
- Varenicline for cognitive impairment in people with schizophrenia: systematic review and meta-analysis.Psychopharmacology · 2020Pooled it
- Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2015Pooled it
- The effectiveness and safety of combining varenicline with nicotine e-cigarettes for smoking cessation in people with mental illnesses and addictions: study protocol for a randomised-controlled trial.BMC public health · 2018Trial
- Predictors of smoking reduction outcomes in a sample of 287 patients with schizophrenia spectrum disorders.European archives of psychiatry and clinical neuroscience · 2017Trial
- Effects of varenicline on the serum levels of olanzapine in male patients with Schizophrenia: a randomized controlled trial.Frontiers in psychiatry · 2023Article
- Approved and emerging smoking cessation treatments for people with schizophrenia spectrum disorders: A narrative review.Health psychology research · 2020Article
- Treatment Outcomes of a Multi-Component Mobile Health Smoking Cessation Pilot Intervention for People with Schizophrenia.Journal of dual diagnosis · 2020Article
- Tobacco smoking, related harm and motivation to quit smoking in people with schizophrenia spectrum disorders.Health psychology research · 2020Article
- Patient-Informed Treatment Development of Behavioral Smoking Cessation for People With Schizophrenia.Behavior therapy · 2019Article
- Efficacy and Safety of Varenicline for Smoking Cessation in Schizophrenia: A Meta-Analysis.Frontiers in psychiatry · 2018Article
- Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia: results from the FACE-SZ dataset.European archives of psychiatry and clinical neuroscience · 2017Article
- Smoking Cessation and Electronic Cigarettes in Community Mental Health Centers: Patient and Provider Perspectives.Community mental health journal · 2017Article
- Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence.JAMA psychiatry · 2017Review
- Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic.Molecular psychiatry · 2015Article
- Psychiatrists' self-stigma, the DGPPN guideline for psychosocial interventions, and contemporary treatment strategies.European archives of psychiatry and clinical neuroscience · 2015Article
- T. Kishi and N. Iwata: Varenicline for smoking cessation in people with schizophrenia: systematic review meta-analysis.European archives of psychiatry and clinical neuroscience · 2015Article
- E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial.Tobacco induced diseases · 2015Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We performed an updated meta-analysis of randomized double-blind placebo-controlled trials (RCTs) on the effects of varenicline adjuvant therapy for smoking cessation in people with schizophrenia, on the basis of a previous meta-analysis (Tsoi in Cochrane Database Syst Rev 2:CD007253, 2013). We searched PubMed, the Cochrane Library databases, and PsycINFO up to August 1, 2014. RCTs comparing varenicline adjuvant therapy with placebo in schizophrenia were included. The risk ratio (RR), number needed to harm (NNH), and standardized mean differences with its 95% confidence interval (CI) were used. Seven studies (total n = 439), including 6 with only schizophrenia (total n = 352), 1 with both schizophrenia (n = 77) and bipolar disorder (n = 10), were included. Varenicline was not superior to placebo in smoking cessation (RR = 0.79, 95% CI 0.58-1.08, p = 0.14, 5 RCTs, n = 322). Varenicline failed to show its superiority to placebo for overall, positive, negative, and depressive symptoms. Moreover, there was no significant difference in the discontinuation rate due to all causes, clinical deterioration, or side effects between varenicline and placebo. Although varenicline caused less abnormal dreams/nightmares than placebo (RR = 0.47, 95% CI 0.22-0.99, p = 0.05, NNH = not significant, 4 RCTs, n = 288), it caused more nausea (RR = 1.79, 95% CI 1.20-2.67, p = 0.004, NNH = 6, p = 0.004, 6 RCTs, n = 417). We detected no significant difference in suicidal ideation and depression between varenicline and placebo. Our results suggest that although varenicline adjuvant therapy is well tolerated, varenicline is not superior to placebo for smoking cessation in people with schizophrenia. Because of the limited sample sizes of the available studies, future studies will require larger samples to ensure that these findings are generalizable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.